( OTC-PINK:ESALY )

News from Morphotek, Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Dec 11, 2017, 10:00 ET Morphotek And Rockefeller University Form A Sponsored Research Agreement To Study The Immunosuppressive Effects Of The Tumor Shed Antigen CA125 And Its Potential Impact In Future Patient Therapies

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has entered into a Sponsored Research Agreement (SRA) with The Rockefeller...


Dec 07, 2017, 10:00 ET Morphotek To Present Its Proprietary RESPECT™ Antibody-Drug Conjugate (ADC) Technology At The Upcoming Antibody Engineering & Therapeutics Conference In San Diego

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it will present its Residue-Specific Conjugation Technology (RESPECT) at the...


Dec 04, 2017, 10:00 ET Morphotek Announces Initiation Of Phase 1 Study Of Next-Generation Farletuzumab Antibody-Drug Conjugate MORAb-202 In Solid Tumors With Folate Receptor Alpha Expression

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that the first patient has been enrolled into a Phase 1 cancer study of Morphotek's...


Nov 13, 2017, 15:00 ET Morphotek To Present Its Proprietary RESPECT™ Antibody Drug Conjugate (ADC) Technology At The Upcoming 9th Annual PEGS Europe In Lisbon

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it will present its Residue-Specific Conjugation Technology (RESPECT) at the 9th...


Sep 19, 2017, 10:00 ET Morphotek To Present Preclinical Data On Antibody-Drug Conjugate MORAb-202 At The Upcoming 8th Annual World ADC In San Diego

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it will present preclinical data on its investigational antibody-drug conjugate...


Sep 06, 2017, 10:00 ET Morphotek Announces Collaboration Agreement With The Johns Hopkins University To Research And Develop Novel Monoclonal Antibody-Based Therapies Targeting Missplicing-Associated Surface Antigens

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it entered into an agreement with the Johns Hopkins University School of...


Sep 05, 2017, 10:00 ET Morphotek®, Inc. Announces an Agreement with Fujirebio Diagnostics, Inc. to Commercialize the CA125 II Assay as a Companion Diagnostic for Farletuzumab®

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it entered into a collaboration and license agreement with Fujirebio...


Jul 11, 2017, 10:00 ET Morphotek Announces Publication Uncovering One Of The Mechanisms By Which The Tumor-Produced CA125 Protein Suppresses Immune-Mediated Killing Via Farletuzumab

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that a publication entitled "Tumor antigen CA125 suppresses antibody-dependent...


Apr 26, 2017, 10:00 ET Morphotek To Present Its Proprietary RESPECT™ Antibody Drug Conjugate (ADC) Technology At The Upcoming 13th Annual PEGS Summit In Boston

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it will present its REsidue-SPEcific Conjugation Technology (RESPECT™) at the...


Apr 03, 2017, 09:00 ET Morphotek Launches Antibody Drug Conjugate Services Business

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today the launch of its Antibody Drug Conjugate (ADC) Services business based on its...


Mar 28, 2017, 10:00 ET Morphotek to Present Three Posters at the Upcoming American Association for Cancer Research (AACR) Annual Meeting 2017

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it will present three posters at the Annual Meeting of the American...


Mar 22, 2017, 10:00 ET Morphotek And Sandy Rollman Ovarian Cancer Foundation Launch Educational Resource On Clinical Trials

Morphotek®, Inc., a subsidiary of Eisai Inc., and the Sandy Rollman Ovarian Cancer Foundation (SROCF) announced today the launch of a resource to...


Oct 03, 2016, 09:00 ET Morphotek and Eurofarma Laboratórios S.A. Sign Exclusive Licensing Agreement for Farletuzumab in Latin America

 Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it signed an exclusive licensing agreement with Eurofarma...


Sep 13, 2016, 10:00 ET Morphotek Announces Sponsored Research Agreement With Fox Chase Cancer Center To Study Immunosuppressive Effects Of Tumor Shed Antigens To Improve Future Patient Therapies

 Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it entered into a Sponsored Research Agreement (SRA) with Fox Chase...


Feb 03, 2016, 09:00 ET Morphotek Announces Collaboration with Mayo Clinic to Apply Its Folate Receptor Alpha Diagnostic Assays in a Phase II Clinical Trial in Triple-Negative Breast Cancer

 Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it is collaborating with researchers Keith L. Knutson, Ph.D. in the...


Dec 16, 2015, 09:00 ET Morphotek®, Inc. Announces An Agreement With Biocare Medical, LLC To Develop And Commercialize A Diagnostic Kit For Detection Of Mesothelin In Malignant Tissues

 Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it entered into a second collaboration and license agreement with...


Dec 07, 2015, 09:00 ET Morphotek Announces Phase 1 Results From MORAb-022-001 Trial In Healthy Subjects And Patients With Mild-To-Moderate Rheumatoid Arthritis

 Morphotek®, Inc., a subsidiary of Eisai Inc., announced today results from Study MORAb-022-001, a single-dose, dose-ascending,...


Dec 03, 2015, 09:00 ET Morphotek Announces Collaboration Agreement With University Of Wisconsin-Madison To Study The Immunosuppressive Effects Of CA125 Tumor Antigen On Immune-Based Therapies For Ovarian Cancer

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it entered into a collaborative research agreement with University of...


Nov 18, 2015, 09:00 ET Morphotek®, Inc. Announces Initiation Of Amatuximab Study In First-Line, Unresectable, Malignant Pleural Mesothelioma Patients

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has enrolled the first patient in the randomized, double-blind...


Nov 17, 2015, 09:00 ET Morphotek Announces Collaboration Agreement With University of Gothenburg To Develop Farletuzumab, An Investigational Anti-Folate Receptor Alpha Monoclonal Antibody, For Alpha-Particle Radioimmunotherapy In Ovarian Cancer

 Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it entered into an agreement with the Targeted Alpha Therapy Group...


Nov 09, 2015, 09:00 ET Morphotek®, Inc. Announces A License Agreement With Blaze Bioscience, Inc. For The Development Of Novel Oncology Imaging Technology

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has entered into a license agreement with Blaze Bioscience, Inc. of...


Oct 26, 2015, 09:00 ET Morphotek®, Inc. Presents Preclinical Findings At ESGO 19 On The Potential Immunosuppressive Effects Of The CA125 Tumor Antigen On Farletuzumab, An Investigational Anti-Folate Receptor Alpha Antibody

 Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has presented preclinical data showing the immunosuppressive...


Oct 09, 2013, 09:05 ET Morphotek, Inc. Announces Initiation Of A New MORAb-004 Phase I Study In Pediatric Patients With Relapsed/Refractory Solid Tumors

 Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that the Children's Oncology Group (COG) has opened enrollment in a Phase 1...


Jun 25, 2013, 09:30 ET Morphotek, Inc. Announces Initiation Of A Phase I Study For MORAb-066

 Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that the Sarah Cannon Research Institute in Nashville, Tennessee has opened...


Aug 27, 2012, 09:00 ET Morphotek®, Inc. Announces Initiation of MORAb-004 Phase II Study in Metastatic Soft Tissue Sarcoma

 Morphotek®, Inc. announced today that it has commenced a multi-center, Phase II study evaluating the safety and efficacy of MORAb-004...